Modulating BET Bromodomain Inhibitor ZEN-3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform-Reference-Cited by-同舟云学术

Modulating BET Bromodomain Inhibitor ZEN-3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform

Published:2018-08-29 Issue:6 Volume:1 Page:1800104
ISSN:2366-3987
Container-title:Advanced Therapeutics
language:en
Short-container-title:Adv. Therap.

Author:

Pantuck Allan J.¹²,Lee Dong-Keun³,Kee Theodore⁴³,Wang Peter⁵,Lakhotia Sanjay⁶⁷,Silverman Michael H.⁶⁷,Mathis Colleen¹,Drakaki Alexandra¹⁸,Belldegrun Arie S.¹,Ho Chih-Ming²³⁹,Ho Dean⁴

Affiliation:

1. Ronald Reagan UCLA Medical Center; Department of Urology; David Geffen School of Medicine; Institute of Urologic Oncology; University of California; 757 Westwood Plaza Los Angeles CA 90095 USA

2. Jonsson Comprehensive Cancer Center; University of California; 10833 Le Conte Ave Los Angeles CA 90095 USA

3. Department of Bioengineering; Henry Samueli School of Engineering and Applied Science; University of California; 410 Westwood Plaza Los Angeles CA 90095 USA

4. Department of Biomedical Engineering; National University of Singapore; Singapore 117583 Singapore

5. Department of Chemical and Biomolecular Engineering; Henry Samueli School of Engineering and Applied Science; University of California; 5531 Boelter Hall Los Angeles CA 90095 USA

6. Zenith Epigenetics; Suite 4010, 44 Montgomery Street San Francisco CA 94104 USA

7. Zenith Epigenetics; 300, 4820 Richard Road SW Calgary AB T3E 6L1 Canada

8. Department of Medicine; Division of Hematology & Oncology; David Geffen School of Medicine; University of California; 10833 Le Conte Ave. 11-934 Factor Bldg. Los Angeles CA 90095 USA

9. Department of Mechanical and Aerospace Engineering; Henry Samueli School of Engineering and Applied Science; University of California; 420 Westwood Plaza Los Angeles CA 90095 USA

Funder

V Foundation for Cancer Research

Wallace H. Coulter Foundation

Publisher

Wiley

Subject

Pharmacology (medical),Biochemistry, medical,Genetics(clinical),Pharmaceutical Science,Pharmacology,Medicine (miscellaneous)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/adtp.201800104/fullpdf

Reference32 articles.

1. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy.

2. Output-driven feedback system control platform optimizes combinatorial therapy of tuberculosis using a macrophage cell culture model

3. Individualizing liver transplant immunosuppression using a phenotypic personalized medicine platform

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Personalized dose selection for the first Waldenström macroglobulinemia patient on the PRECISE CURATE.AI trial;npj Digital Medicine;2024-08-27

2. Machine Learning Methods for Precision Dosing in Anticancer Drug Therapy: A Scoping Review;Clinical Pharmacokinetics;2024-08-17

3. N-of-1 health optimization: Digital monitoring of biomarker dynamics to gamify adherence to metabolic switching;PNAS Nexus;2024-05-30

4. Dynamic, personalized dose selection platform, CURATE.AI, in patients with solid tumors: case series and pilot feasibility trial;2024-05-30

5. Catalyzing innovation in cancer drug discovery through artificial intelligence, machine learning and patency;Pharmaceutical Patent Analyst;2024-05-21